| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4188
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4188
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate |
2009-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2011-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2011529467-A |
| titleOfInvention |
Use of CDK inhibitors for the treatment of glioma |
| abstract |
The present invention provides low molecular weight ATP competitive CDK inhibitors capable of crossing the blood brain barrier for use in the treatment of malignant gliomas, particularly glioblastomas. The compound can be administered with one or more agents selected from the group consisting of cytotoxic or anti-mitotic agents and ionizing radiation. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7233743-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2012525345-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2016505588-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020530491-A |
| priorityDate |
2008-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |